Health
Commission authorizes first treatment for serious chronic lung disease
The Commission has granted EU marketing authorization for ‘brensocatib', a new active substance for the treatment of chronic progressive lung disease (non-cystic fibrosis bronchiectasis, or NCFB) in patients aged 12 years and older. The estimated number of patients with NCFB in the EU ranges from 400,000 to three million. The disease causes damaged airways and severe pulmonary dysfunction, often leading to chronic cough and airflow obstruction. It is driven by repeated infections and inflammation, and can be triggered by several causes such as respiratory infections, autoimmune diseases, and immunodeficiency disorders.
As there are currently no approved treatments directly addressing this disease, today's authorisation responds to an important unmet medical need.
The authorization is based on a positive scientific assessment from the European Medicines Agency (EMA). Brensocatib is subject to medical prescription and may cause some side effects which are listed in the product information leaflet. It should not be used in pregnancy.
The Commission decision will be available soon at: Union Register of medicinal products.
Share this article:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Stepping out...to get the UK back in European Union
Energy use in the industry sector continues to decline
Improving energy efficiency of buildings to reduce bills and save energy
DG Translation in a city near you: June events
The role of quality assurance in advancing inclusive upper secondary VET in Slovenia
Europe must not turn its back on rural women’s empowerment
Commission accelerates transition away from animal testing in chemical safety assessments
Counterfeit cigarettes drive illicit tobacco trade to highest level in a decade, new study claims
Inconvenient questions about Andorra and San Marino that Brussels should be asking
How digital wallets are changing the way Welsh consumers pay for online services
Impasse in European Union Tobacco Tax Reform: The Swedish veto
EU Cybersecurity Act could expose member states to costly investment treaty claims, legal opinion warns
Várhelyi says unilateral measures by the US against the EU ‘would not be justified’
Libya’s fuel crisis offers lessons for energy security on both sides of the Mediterranean
490+ experts call for €10 billion ring-fenced health allocation in EU budget
ENVI opinion signals early resistance to Biotech Act SPC extension
Kazakhstan reforms under scrutiny at Brussels Press Club round table
Japan should face up to history and contribute more to regional peace
Ambassador calls for 'speeding up' of co-operation between EU and Kazakhstan
Timur Turlov at Smart Moves Summit 2025: How chess can transform global education
Shevtsova’s case: Out-of-court sanctions dismantling trust in Ukrainian cause
The future of European transport
Trump Vs Trueman
